Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.210
-0.010 (-0.82%)
At close: Jun 17, 2025, 4:00 PM
1.210
0.00 (0.00%)
After-hours: Jun 17, 2025, 5:55 PM EDT

Acrivon Therapeutics Stock Forecast

ACRV's stock price has decreased by -83.31% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 7 analysts that cover Acrivon Therapeutics stock have a consensus rating of "Buy" and an average price target of $17.6, which forecasts a 1354.55% increase in the stock price over the next year. The lowest target is $9 and the highest is $27.

Price Target: $17.6 (+1354.55%)
Analyst Consensus: Buy
Target Low Average Median High
Price $9.00 $17.6 $17 $27
Change +643.80% +1354.5% +1305.0% +2131.4%
* Price targets were last updated on May 15, 2025.

Analyst Ratings

The average analyst rating for Acrivon Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Jan '25Feb '25Mar '25Apr '25May '25Jun '25
Strong Buy 222222
Buy 444444
Hold 000011
Sell 000000
Strong Sell 000000
Total 666677

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Jones Trading
Jones Trading
Hold
Downgrades
n/a
Hold Downgrades n/a n/a May 16, 2025
Oppenheimer
Oppenheimer
Buy
Maintains
$10$9
Buy Maintains $10$9 +643.80% May 15, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$19
Strong Buy Reiterates $19 +1,470.25% Mar 28, 2025
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterates
n/a
Buy Reiterates n/a n/a Mar 26, 2025
Citizens Capital Markets
Citizens Capital Markets
Buy
Reiterates
$17
Buy Reiterates $17 +1,304.96% Mar 26, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
from 109.92M
Revenue Next Year
n/a
EPS This Year
-2.45
from -2.38
EPS Next Year
-2.56
from -2.45
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027 FY 2028 FY 2029
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027 Dec 31, 2028 Dec 31, 2029
Revenue
147.90K1.92M12.78M45.14M109.92M
Revenue Growth
-1,200.20%564.53%253.22%143.52%---
EPS
-3.70-9.32-7.56-2.74-2.38-2.45-2.56-2.55
EPS Growth
--------
Forward PE
--------
No. Analysts
-----11119
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 1.2M 11.0M 45.1M
Avg 147,900 1.9M 12.8M
Low n/a n/a n/a

Revenue Growth

Revenue Growth 20252026202720282029
High
-98.9%
7,354.4%
2,246.2%
Avg
-99.9%
1,200.2%
564.5%
Low - - -

EPS Forecast

EPS 20252026202720282029
High -2.21 -2.14 -1.88
Avg -2.45 -2.56 -2.55
Low -2.84 -3.43 -3.97

EPS Growth

EPS Growth 20252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.